Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Clinical Implications of Programmed Death-Ligand 2 (PD-L2) Expression as an Independent Prognostic Marker in Lung Adenocarcinoma: Different Characteristics of PD-L2-Positive Patients from Those with Programmed Death-Ligand 1

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Takada K, Okamoto T, Shoji F, et al. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. J Thorac Oncol. 2016;11(11):1879–90.

    Article  Google Scholar 

  2. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.

    Article  CAS  Google Scholar 

  3. Takamori S, Takada K, Azuma K, et al. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Ann Surg Oncol. 2019;26:1916–1924.

    Article  Google Scholar 

  4. Kenkel JA, Tseng WW, Davidson MG, et al. An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Cancer Res. 2017;77(15):4158–70.

    Article  CAS  Google Scholar 

  5. Yearley JH, Gibson C, Yu N, et al. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clin Cancer Res. 2017;23(12):3158–67.

    Article  CAS  Google Scholar 

  6. Takamori S, Takada K, Toyokawa G, et al. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. Anticancer Res. 2018;38(10):5897–901.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Shinkichi Takamori PhD & Yoshihiko Maehara PhD

  2. Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka, Japan

    Kazuki Takada PhD

Authors
  1. Shinkichi Takamori PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuki Takada PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiko Maehara PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinkichi Takamori PhD.

Ethics declarations

Disclosures

Shinkichi Takamori, Kazuki Takada, and Yoshihiko Maehara have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ASO Author Reflections is a brief invited commentary on the article “Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients”, Ann Surg Oncol. 2019;26:1916–1924.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takamori, S., Takada, K. & Maehara, Y. ASO Author Reflections: Clinical Implications of Programmed Death-Ligand 2 (PD-L2) Expression as an Independent Prognostic Marker in Lung Adenocarcinoma: Different Characteristics of PD-L2-Positive Patients from Those with Programmed Death-Ligand 1. Ann Surg Oncol 26 (Suppl 3), 668–669 (2019). https://doi.org/10.1245/s10434-019-07680-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-019-07680-6

Search

Navigation